Absci Corp logo

Absci Corp

ABSI
Healthcare|Biotechnology|USA
$10.60
-0.87 (-7.59%)
Tangible Book
$0.85

Financials

Financial Snapshot

Market Cap
$1.79B
Enterprise Value
$121.3M
Revenue (TTM)
$1.8M
Net Income (TTM)
$-118.4M
Cash & Equivalents
Net Cash/Share
$0.66
Free Cash Flow (TTM)
$-98.5M
Operating CF (TTM)
$-97.4M
Debt/Equity
0.03

Cash Runway & Burn Rate

Cash on Hand
$0.00
Quarterly Burn
$24.3M
Monthly Burn
$8.1M
Est. Runway
MetricTrend2019202020212022202320242025TTM
Cash & Investments
$13.1M$69.9M$252.6M$164.4M$97.7M$112.4M$144.3M$125.7M
Operating Cash Flow
$-6.0M$-11.0M$-60.6M$-81.3M$-64.6M$-72.4M$-92.9M$-97.4M
Free Cash Flow
$-7.1M$-13.2M$-98.6M$-97.5M$-65.5M$-72.8M$-94.0M$-98.5M
Capital Expenditure
$-1.1M$-2.2M$-38.0M$-16.2M$-860.0K$-404.0K$-1.1M$-1.1M
Financing Cash Flow
$12.7M$71.0M$336.2M$5.2M$-4.5M$82.5M$105.9M$70.7M

R&D Spending

R&D (TTM)
$84.3M
R&D Intensity
4593.1%
R&D Growth YoY
+3.6%
MetricTrend2019202020212022202320242025TTM
Revenue
$2.1M$4.8M$4.8M$5.7M$5.7M$4.5M$2.8M$1.8M
R&D Expense
$4.3M$11.4M$44.6M$58.9M$48.1M$63.9M$81.4M$84.3M
R&D % of Revenue
209.3%239.5%932.4%1025.0%840.6%1408.4%2907.8%4593.1%
SG&A
$3.5M$5.5M$28.8M$40.6M$37.8M$36.2M$35.1M$34.6M

Income Statement

MetricTrend2019202020212022202320242025TTM
Revenue
$2.1M$4.8M$4.8M$5.7M$5.7M$4.5M$2.8M$1.8M
Cost of Goods Sold
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Gross Profit
$2.1M$4.8M$4.8M$5.7M$5.7M$4.5M$2.8M$1.8M
R&D
$4.3M$11.4M$44.6M$58.9M$48.1M$63.9M$81.4M$84.3M
SG&A
$3.5M$5.5M$28.8M$40.6M$37.8M$36.2M$35.1M$34.6M
Operating Income
$-6.3M$-13.3M$-75.2M$-106.8M$-94.2M$-108.9M$-125.4M$-128.5M
Interest Expense
$-268.0K$-634.0K$-3.4M$-972.0K$-1.0M$-565.0K$-209.0K$-148.0K
Pretax Income
$-6.6M$-14.4M$-109.9M$-105.4M$-110.5M$-103.0M$-115.1M$-118.3M
Net Income
$-6.6M$-14.4M$-101.0M$-104.9M$-110.6M$-103.1M$-115.2M$-118.4M
EPS (Diluted)
-0.26-0.55-2.08-1.15-1.20-0.94-0.84-0.83
EBITDA
$-5.8M$-12.6M$-99.8M$-91.3M$-95.5M$-89.1M$-103.2M$-106.8M
Shares Out. (M)
90.3890.3849.6990.8592.03110.24136.78152.96

Balance Sheet

MetricTrend2019202020212022202320242025TTM
Cash & Equivalents
$13.1M$69.9M$252.6M$60.0M$72.4M$41.2M$20.0M$8.6M
Marketable Securities
$0.00$0.00$0.00$104.5M$25.3M$71.2M$124.3M$117.1M
Total Current Assets
$13.6M$73.2M$273.1M$186.9M$120.6M$133.8M$149.6M$132.0M
Total Assets
$19.5M$88.6M$426.2M$321.0M$217.3M$213.6M$216.3M$195.6M
Total Current Liabilities
$3.5M$10.1M$33.9M$30.3M$29.6M$28.7M$22.8M$20.0M
Long-Term Debt
$1.7M$4.1M$1.1M$8.0M$4.7M$1.3M$0.00$0.00
Total Liabilities
$60.6M$178.0M$60.1M$46.6M$41.1M$34.5M$26.8M$23.6M
Stockholders' Equity
$-41.2M$-89.4M$366.1M$274.4M$176.2M$179.1M$189.4M$172.0M
Retained Earnings
$-41.4M$-90.1M$-191.0M$-295.9M$-406.5M$-509.6M$-624.8M$-654.4M

Cash Flow Statement

MetricTrend2019202020212022202320242025TTM
Operating Cash Flow
$-6.0M$-11.0M$-60.6M$-81.3M$-64.6M$-72.4M$-92.9M$-97.4M
Capital Expenditure
$-1.1M$-2.2M$-38.0M$-16.2M$-860.0K$-404.0K$-1.1M$-1.1M
Free Cash Flow
$-7.1M$-13.2M$-98.6M$-97.5M$-65.5M$-72.8M$-94.0M$-98.5M
Investing Cash Flow
$-1.1M$-2.2M$-67.4M$-127.0M$81.9M$-41.6M$-50.2M$-27.8M
Financing Cash Flow
$12.7M$71.0M$336.2M$5.2M$-4.5M$82.5M$105.9M$70.7M
Issuance of Stock
$0.00$0.00$210.4M$656.0K$862.0K$82.4M$105.8M$72.1M
Repurchase of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Issuance of Debt
$2.8M$3.2M$125.0M$12.0M$0.00$0.00$0.00$0.00
Payments of Debt
$-377.0K$-1.6M$-4.1M$-7.5M$-5.3M$-4.0M$-3.2M$-2.8M
Stock Based Comp.
$42.0K$420.0K$10.6M$12.5M$11.4M$19.5M$18.3M$17.8M
Net Change in Cash
$5.6M$57.8M$208.2M$-203.1M$12.8M$-31.5M$-37.1M$-54.4M

Dilution Tracker

Shares outstanding grew 207.9% over 5 years — significant dilution
Shares Outstanding
153M
5-Year Share Growth
+207.9%
Stock Issuance (TTM)
$72.1M
MetricTrend2019202020212022202320242025TTM
Shares Out. (M)
90.3890.3849.6990.8592.03110.24136.78152.96
YoY Change %
0.0%-45.0%82.8%1.3%19.8%24.1%11.8%
Stock Issuance
$0.00$0.00$210.4M$656.0K$862.0K$82.4M$105.8M$72.1M
Stock Repurchase
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Based Comp.
$42.0K$420.0K$10.6M$12.5M$11.4M$19.5M$18.3M$17.8M

Margins & Profitability

MetricTrend2019202020212022202320242025TTM
Gross Margin %
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Operating Margin %
-304.1%-278.3%-1573.4%-1857.5%-1647.1%-2401.6%-4479.2%-7000.8%
Net Margin %
-319.6%-300.3%-2111.3%-1825.4%-1933.6%-2274.1%-4113.7%-6450.8%
EBITDA Margin %
-282.8%-263.3%-2086.4%-1588.5%-1669.4%-1964.8%-3684.4%-5816.9%
FCF Margin %
-346.1%-275.1%-2062.8%-1696.8%-1145.4%-1605.8%-3358.3%-5365.2%
ROE %
0.0%0.0%-73.0%-32.8%-49.1%-58.0%-62.5%-62.7%
ROA %
-33.8%-26.6%-39.2%-28.1%-41.1%-47.9%-53.6%-53.9%
R&D / Revenue--------

Valuation

P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S815.00
Historical14.04 / 78.39 / 893.85
Industry Med.9.49
P/B9.57
Historical0.46 / 1.94 / 10.50
Industry Med.2.93
EV/EBITDA-15.67
Historical-45.43 / -2.73 / 0.10
Industry Med.13.02
EV/Revenue911.50
Historical-1.40 / 57.50 / 911.50
Industry Med.8.59
P/FCF
Historical / /
Industry Med.27.13

Intrinsic Value Models

Tangible Book
$0.85
Net Current Assets
$0.700
Net-Net Working Capital
$0.66
MetricTrend2019202020212022202320242025TTM
PE RatioN/AN/AAt LossAt LossAt LossAt LossAt LossAt Loss
PS Ratio
0.000.0085.4233.3367.7463.90174.50815.00
PB Ratio
0.000.002.070.712.221.692.799.57
EV/EBITDA
0.000.00-5.28-0.58-3.24-2.24-3.78-15.67
EV/Revenue
0.000.00110.249.1654.0744.08139.21911.50

Analyst Estimates & Quality

Altman Z-Score
39.61
Safe
Piotroski F-Score
3
Weak
Beneish M-Score
-4.87
Unlikely Manipulator

Forward Estimates

MetricCurrent YearNext Year2 Years Out
Revenue$7.19M$22.22M$49.09M
Net Income$-123.28M$-112.35M$-153.22M
EPS-0.81-0.66-0.73
Book Value per Share1.311.381.43
Operating Cash Flow per Share-0.68-0.600.00
Operating CF$-104.01M$-91.78M$0.00M

Dividends

Revenue Segments

By Business

Segment2025
Single Segment$2.8M

By Geography

Segment2025
United States$2.8M